Free tool
FAERS Monitor: Rapiblyk
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217202 or its brand name (Rapiblyk, Landiolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
84
Serious
81
96% of reports
Hospitalization
56
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective35
- off label use12
- bradycardia8
- ventricular fibrillation7
- condition aggravated6
- drug ineffective for unapproved indication6
- atrial fibrillation5
- cardiac failure5
- hypotension5
- product use in unapproved indication5
- cardiogenic shock4
- electrocardiogram qt prolonged4
- stress cardiomyopathy4
- tachycardia4
- torsade de pointes4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 12 |
| 2022 | 25 |
| 2024 | 14 |
| 2025 | 9 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stress cardiomyopathySignal | 4 | 172.4 | 66.2 | 521 |
| ventricular fibrillationSignal | 7 | 157.9 | 77.7 | 940 |
| torsade de pointesSignal | 4 | 127.8 | 49.1 | 384 |
| cardiogenic shockSignal | 4 | 69.8 | 26.8 | 207 |
| bradycardiaSignal | 8 | 37.8 | 19.5 | 251 |
| electrocardiogram qt prolongedSignal | 4 | 27.9 | 10.7 | 79 |
| drug ineffective for unapproved indicationSignal | 6 | 27.4 | 12.7 | 128 |
| cardiac failureSignal | 5 | 15.6 | 6.7 | 55 |
| atrial fibrillationSignal | 5 | 12.9 | 5.5 | 44 |
| tachycardiaSignal | 4 | 11.3 | 4.3 | 28 |
| drug ineffectiveSignal | 35 | 6.6 | 5.2 | 173 |
| hypotensionSignal | 5 | 6.2 | 2.7 | 17 |
| product use in unapproved indicationSignal | 5 | 5.1 | 2.2 | 13 |
| condition aggravatedSignal | 6 | 4.9 | 2.3 | 15 |
| off label useSignal | 12 | 3.4 | 2.0 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.